Are antibody-based therapeutics and venture capital a bad mix?

Sunstone monitors and analyzes all M&A transactions for therapeutic companies HQ’ed in Europe, with an exit transaction value exceeding EUR 50M. Upon fragmenting the 43 transactions executed between 2010 and 2020 by modalities, we were surprised to observe that only 4 of these involved therapeutic antibodies, relative to 24 small molecules!

FDA in the same period approved approximately one antibody for every three small molecules! Why is European venture capital not having more success with antibodies? Is the CMC too costly?

Is this a European phenomenon caused by smaller funds and smaller deployment of capital? Have Venture Capital in the US been more successfully deploying venture capital in therapeutic antibodies?

On a positive note, several of these M&As target novel modalities, highlighting the important role of European venture capital in seeding the pharmaceutical R&D ecosystem with new innovations!

What do you think?
Let us know in our feed on LinkedIn:

5 latest press releases

Teitur Trophics Raises EUR 28M in Series A Financing to advance the development and treatment for neurodegenerative diseases

Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and...

Galecto Completes Enrollment in Phase 1b_2a GULLIVER-2 Trial of its Selective, Oral Galectin-3 Inhibitor GB1211 in Liver Cirrhosis

BOSTON, March 29, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced it has completed enrollment in Parts 2 and 3 of its ongoing 3-part...

Sunstone Life Science Ventures is looking for a Student Assistant

No longer accepting applications We are looking for a student to join our team for approximately 8 hours a week. As part of the team, you will play a pivotal role in the management of our deal flow, which lies in the order of 400-500 opportunities every year....

Sunstone announce new investment in immuno-oncology company STipe Therapeutics

Sunstone Life Science Ventures today announce it has invested in new portfolio company Stipe Therapeutics ApS (“STipe”), an immuno-oncology company dedicated to developing novel cancer therapeutics based on its first class drugs modulating the STING pathway.

Zealand Pharma achieves primary and all key secondary endpoints in pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia

Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces positive results in the pediatric Phase 3 trial with dasiglucagon for severe hypoglycemia...

5 latest articles

Biotech startups in Scandinavia have 460 MEUR at hand – but burn is up – and runway the shortest in 3 years

As the market continues to fluctuate and geopolitical issues continue to impact the economy, it's important to take a closer look at the state of pre-commercial life science companies. At Sunstone, we assisted companies in our portfolio with listings and refinancing,...

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?

Unmet medical needs in cardiovascular sub-populations – an opportunity for VCs?  For the past 5 months we have had the pleasure of having Philip Brainin as intern at Sunstone Life Science Ventures. Apart from bringing valuable insights to our daily activities, he has...

Why do VC’s not cut losses in time?

Why do VC’s not cut losses in time?  A clinical trial is a very expensive experiment for testing a hypothesis, while hoping for a positive outcome. However, if well designed, a negative outcome could increase the potential for a positive outcome in a subsequent trial....

Are some diseases associated with a higher risk of venture capital losses?

Are some diseases associated with a higher risk of venture capital losses?  Before summer we posted a study correlating venture capital losses in drug development with the magnitude of funding of clinical trials. We have used two approaches to find losses: 1)...

Do compromises in clinical trials cause Venture Capital losses?

Do compromises in clinical trials cause Venture Capital losses? In 2020 and 2021 Sunstone looked in depth at drug development venture-backed successes to find usable attributes and learn from the past. We have now turned the analysis up-side down and looked at the...

Who is in the driver’s seat of our industry?

A recent analysis from Pharma Intelligence | Informa 2021 highlights the current trends of pipeline products (top panel). We have subsequently surveyed Sunstone’s incoming deal flow for the same period and noted the correlation for the top 3 categories with oncology...